+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P10554(JADE1 Antibody) at dilution 1/130. (Original magnification: ×200)    

  
  

**Background of JADE1 Antibody**

JADE1 (gene name: *PHF16*) is a PHD zinc finger-containing protein implicated in transcriptional regulation, chromatin remodeling, and cancer biology. It was initially identified as a binding partner of the von Hippel-Lindau (VHL) tumor suppressor protein, which is mutated in hereditary renal cell carcinoma. JADE1 interacts with VHL as part of the ubiquitin ligase complex, modulating hypoxia-inducible factor (HIF) signaling and influencing cellular responses to oxygen levels.

JADE1 is structurally characterized by tandem plant homeodomains (PHDs), which mediate chromatin interactions, and a coiled-coil domain for protein oligomerization. Studies suggest its involvement in cell cycle regulation, apoptosis, and DNA damage repair. In cancer, JADE1 exhibits dual roles: it acts as a tumor suppressor in renal and liver cancers, where its expression is often downregulated, but may promote tumorigenesis in other contexts, such as breast cancer.

Antibodies targeting JADE1 are widely used in research to detect its expression and localization via techniques like immunohistochemistry (IHC), Western blot (WB), and immunofluorescence (IF). These tools help elucidate JADE1's role in epigenetic regulation, its interaction with histone modifiers (e.g., HBO1 acetyltransferase), and its potential as a biomarker or therapeutic target in cancers and other diseases linked to chromatin dysregulation.